Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer
- Leticia De Mattos-ArrudaAffiliated withMedical Oncology Department, Vall d’Hebron Institute of Oncology, Vall D’Hebron University HospitalUniversitat Autònoma de Barcelona Email author
- , Javier CortesAffiliated withMedical Oncology Department, Vall d’Hebron Institute of Oncology, Vall D’Hebron University HospitalMedica Scientia Innovation Research (MedSIR)
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Targeting the human epidermal growth factor receptor (HER) family of tyrosine kinase receptors has proven to be effective as a therapeutic strategy for HER type 2 (HER2)-positive breast cancer. Since resistance to trastuzumab occurs relatively frequently, particularly in the metastatic setting, novel anti-HER2 targeted therapies with complementary and/or synergistic mechanisms of action have been under development. Pertuzumab, a HER2-targeted monoclonal antibody that prevents HER2 dimerisation, is the first of a class of promising targeted agents for the treatment of HER2-positive breast cancer.
A review of the biomedical literature published prior to February 2013 was conducted in English using PubMed. ClinicalTrials.gov was searched for appropriate clinical trials. The search terms used included breast neoplasm, pertuzumab, dimerisation, and HER2-positive. Abstracts of studies presented at the ASCO and ESMO Annual Meetings, and San Antonio Breast Cancer Symposium were also included.
Pertuzumab represents a novel anti-HER2 targeted therapy for HER2-positive breast cancers. In this article, we describe the mechanism of action of pertuzumab, as well as its drug development process and preclinical testing results. Based on the results of ancillary studies, dual inhibition using pertuzumab and trastuzumab was shown to be effective for the management of HER2-positive metastatic breast cancers pre-treated with trastuzumab-based therapy. For the first-line setting, the combination of both pertuzumab and trastuzumab with docetaxel (CLEOPATRA trial; clinical evaluation of pertuzumab and trastuzumab) has changed the paradigm of patient management.
Pertuzumab provided a more comprehensive inhibition of HER2-driven signalling pathways. When administered together with trastuzumab, pertuzumab represent a significant advancement for the treatment of HER2-positive metastatic breast cancer patients.
KeywordsDimerisation HER2 Metastatic breast cancer Pertuzumab
- Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer
Advances in Therapy
Volume 30, Issue 7 , pp 645-658
- Cover Date
- Print ISSN
- Online ISSN
- Springer Healthcare
- Additional Links
- Metastatic breast cancer
- Industry Sectors
- Author Affiliations
- 1. Medical Oncology Department, Vall d’Hebron Institute of Oncology, Vall D’Hebron University Hospital, Barcelona, Spain
- 2. Universitat Autònoma de Barcelona, Barcelona, Spain
- 3. Medica Scientia Innovation Research (MedSIR), Barcelona, Spain